

ScinoPharm Management Presentation

May 9, 2017



Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. ("ScinoPharm").

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein.

The **information contained** in this presentation **is** ScinoPharm's **confidential** information. Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or will be made in or in relation to, and no responsibility or liability is or will be accepted by the Company as to, the accuracy or completeness of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this presentation include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words "believes", "anticipates", "plans", "expects" and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management's plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from those implied by such forward-looking statements.



Table of Contents

- Overview of ScinoPharm
- Financial & Operating Results in Q1, 2017
- Business Updates



Overview of ScinoPharm

Business Overview


- Company specializes in high potency (steroid/cytotoxic) APIs and is expanding into sterile/aseptic injectable formulations
- Facility & organization established in Taiwan and expanding in China with a new GMP plant in Changshu & marketing base in Shanghai
- 72 generic APIs in current portfolio with 25 APIs launched; 53 US DMFs filed (759 DMFs WW), 32 US DMFs in oncology APIs. 100+ NCE CRAM projects, with 5 APIs launched and 5 in phase III for NDA filing in 1-3 years
- Fully compliant with world-class cGMPs and international regulatory requirements; Certified by US FDA, EMA, EDQM, Australian TGA, Japanese PMDA




World Class API Facilities

Taiwan	China
 6.6 hectares of land, 330K sq.ft. facilities with >200M³ reactor volume 	6.7 hectares of land with > 250M ³ reactor volume
5 of 16 production lines equipped with high potency capabilities for cytotoxic/steroids	3 of 7 production lines equipped with high potency capabilities for cytotoxics
Passed US FDA, EMA, EDQM, Australian TGA, Japanese PMDA inspections, & 300+	US FDA approved cGMP facility for intermediates & high potency API
cGMP customer audits	Full scope capabilities in the development
Provides comprehensive contract research & manufacturing services for brand drug companies	 and production of APIs on small to large scales for generic & CRAM markets Global market including China
Global Market	
	HIVER AND THE AND

Strong Generics Product Portfolio



ScinoPharm - Oncology API Leader



We are Transforming our Company

Expanding into formulation business, synergizing with our API business, to maximize ROI

Positioning as a Gateway into China providing Supply-Chain to Multinationals Transforming into a full-scope pharma company by executing "Double A" strategy

Tightening cost control and process optimization with enhanced management

Tapping into formulation space related to our core competencies in high-entry-barrier APIs



Keys to Generic Formulation Business

Opportunity

- Already the leader in providing oncology APIs to regulated markets worldwide
- ✓ Injectable CMOs are in short supply.
- Can be customer's injectables provider by developing formulations using our own oncology APIs or others' APIs, up to and including ANDA filing with FDA

Strategy

- Developing dossiers per our difficult-to-make APIs to increase value proposition in the supply chain
- Targeted delivery & extended release of proven APIs via 505(b)(2) fast track
- Collaborating with startups & research institutes, focusing on un-met oncology medical needs of high prevalence in Asia

Tactics

- Expanding formulation portfolio
- Establishing on-site oncology injectable facility and providing an integrated supply chain
- Promoting our formulations via strategic alliances, especially in China and US/EU

Financial & Operating Results in Q1,2017

Quarterly P&L - Consolidated

In NT\$ million, except for EPS	Q1, 2017 (Reviewed)	Q1, 2016 (Reviewed)	YoY
Operating Revenue 🔸	919	1,022	-10%
Gross Profit	470	431	9%
Gross margin	51%	42%	
Operating Expenses	(249)	(236)	6%
Operating Income	221	195	13%
Operating margin	24%	19%	
Other Rev. (Exp.)	(29)	(4)	
Net Income before Tax	192	191	1%
Net Income after Tax	170	172	-1%
Net margin after tax	19%	17%	
EPS (after tax)	0.22	0.23	

 * Taiwan New Dollar per 1 US Dollar quarterly average: 2017Q1: 30.93, 2016Q1: 33.16



Balance Sheet- Consolidated

In NT\$ million	2017/03/31 (Reviewed)		2016/03/31 (Reviewed)	
Cash and Cash Equivalents	3,715	29%	2,560	21%
Accounts Receivable	635	5%	645	5%
Inventories	1,941	15%	2,167	17%
Long-Term Investments	364	3%	364	3%
Property, Plant & Equipment	5,155	40%	5,361	43%
Other Current/Non-Current Assets	1,043	8%	1,394	11%
Total Assets	12,853	100%	12,491	100%
Current Liabilities	1,692	13%	2,374	19%
Long-Term & Other Liabilities	803	6%	90	1%
Stockholders' Equities	10,358	81%	10,027	80%




Cash Flows- Consolidated

In NT\$ million	Q1, 2017 (Reviewed)	Q1, 2016 (Reviewed)
Cash and cash equivalents at beginning of period	3,707	2,336
Cash flows from operating activities	304	663
САРЕХ	(203)	(264)
Short-term borrowings	(51)	(16)
Long-term borrowings	(41)	-
Others	(1)	(159)
Cash and cash equivalents at end of period	3,715	2,560
Free Cash flow	101	399
		😵 ScinoPi

TWSE 1789

Sales by Business


2017 Q1






Sales by Indications

2017 Q1





Business Updates

Business Growth Drivers

- CRAM has promising development potential in the next three years
 - Focus on small-molecule targeted therapies and CNS agents based on new mode of action
 - Provide integrated service from API to formulation for niche injectables
- Active development of Chinese and Japanese market
 - Target projects to utilize capacity and accelerate growth for Changshu site
 - Develop partnership with major Japanese pharmaceutical companies and international pharmaceutical groups with Japan-based operation site

Deploying the network of development, production and distribution of injectable products

- Build partnerships to speed up the momentum of vertical integration
- Achieve critical mass workforce for in-house injectable plant facility

Continue optimizing existing generic APIs

Maintain the market share and profit of the top 5 marketed products



CRO Phase III Product Portfolio

* Already Filed

Code	Est. NDA Filing Year	Indication	Region	*Regional Sales	Remarks
A	2016*	Infectious Disease	US / EU / Asia	\$1.4 bn	Completed process validation. Anticipated launch in 2017 with demand in tons. Expected revenue of several million USD per year
В	2018	Type I,II Diabetes	US/ EU	\$2.4 bn	Intermediate project made in Changshu site. Expected revenue of several million USD per year after launch
С		Advanced Hepatocellular Carcinoma, Myelofibrosis, Autoimmune disease, etc.		N/A	API project made in Changshu site. CFDA granted accelerated review under its category 1.1 innovative drug. Anticipated launch in 2019 with demand in tons
D	2018	Prostate Cancer	US / EU	\$2.4 bn	Started process validation. Anticipated launch in 2019 and revenue of several million USD per year
E	2018	Parkinson's Disease	US	\$1.0 bn	Novel mechanism with promising demand. Anticipated launch in 2019 with demand in tons. Expected revenue of several million USD per year

* Source: BioMedTracker, GlobalData and DataMonitor



China and Japan Market Development

China

- Accelerate progress to create positive cash flow
- Focus on mid- to late-phase CRO projects. Current portfolio includes agents for oncology, anti-hypertension, and diabetes
- Seek generic APIs/intermediates with large demand to increase production utilization
- Develop partnerships with downstream formulation for collaborative development and registration, realizing shared profit creation

Japan

- Among 20 customers, 6 are top 10 drug firms. Less established players have exited the more concentrated market
- Encourage local generic customers to engage more in direct business
- Support Japanese companies and foreign pharmaceutical companies to enable and extend business outreach
- With the resources in Taiwan and Changshu, API supply is more flexible and can be incorporated to injectable drug product via integrated services



Capturing Chinese Growth on Multiple Fronts

- MNCs and emerging virtual-model players create a sizable demand in high quality API contract manufacturing in China for compliance.
- The review and approval system significantly raises the cost structure & entry barrier in Chinese drug market, with dedication to quality and innovation.
- We have domestic presence plus world-class strengths in:
 - * Global, first-tier customer base
 - * High-technical-barrier oncology APIs
 - * Quality and EHS/GMP compliance



Selected List of CRAM Projects at Changshu

Customer	Project Type	Product Indication/stage	Product Type	Remarks/ Market
Top 10 global pharma	СМО	Approved antidepressant drug in US	GMP Intermediate	Passed Mexican authority (APIF) GMP inspection
Top 5 global pharma	СМО	Approved African sleeping disease drug	ΑΡΙ	Site transfer from Taiwan
Lee's Pharma	CRO / CMO	>15 projects for brain tumors, antibiotic, hypertension, ophthalmology, etc.	ΑΡΙ	China
China pharm company	CRO	Phase II/ III clinical trial for cancer	ΑΡΙ	China
China pharm company	CRO	Phase IIb for age-related macular degeneration	ΑΡΙ	US/China
Taigen Biotech	CRO	Phase II clinical trial for myocardial infarction	ΑΡΙ	China/Taiwan
US-based new drug company	CRO	Phase II clinical trial for prevention of HIV infection	ΑΡΙ	US
Aslan Pharmaceuticals	CRO	Phase II clinical trial for cancer	ΑΡΙ	China/Global
Top 5 global pharma	CRO	Phase III clinical trial for diabetes	Intermediate	US
Top 5 global pharma	CRO	Phase I clinical trial	ΑΡΙ	NA
US NASDAQ listed pharma	CRO	Phase III clinical trial for opioid-induced constipation	Crude API	US
US-based new drug company	CRO	Phase I clinical trial for sickle cell disease	ΑΡΙ	US



Formulation Business Progress

In-house injectable plant

- On schedule to complete equipment assembly and verification, sterility verification, organization, personnel deployment and training, and cGMP system deployment for both vial and cartridge production lines
- Planned kick-off registration batch production by 2017. Expected submission of 1st in-house ANDA in 2018 and subsequent US FDA inspection approval in 2019.


Formulation and collaboration development

- 2 US ANDAs: Oncology product partnership with SAGENT, and ScinoPharmdeveloped Fondaparinux
- 16 co-developed and cost/profit sharing products with various partners
- Niche drugs planned with the indications of cancer, diabetes, osteoporosis and multiple sclerosis. Continue to develop strategic alliances, including ongoing discussions with international major companies for exclusive rights of distribution

Injectable Plant



Aseptic Fill & Finish Service





Strategic Alliance Highlights

* Already launched

Partner	Product	Indications	Region	Launch Year(E)	Remarks	
Genovate	Entecavir	Hepatitis B Virus	Taiwan	2013*	1 st co-developed formulation product launch	
Sagent	Oncology Injectable	Myeloid Leukemia	US	2017	1 st US ANDA filing, triggering US FDA inspection in Changshu, China site	
Foresee	Leuprolide	Prostate cancer	US	2019	505(b)(2) NDA CRAM + Equity	
Coland	Bortezomib	Multiple Myeloma	China	2020	1 st co-developed drug in China to trigger CFDA inspection in Changshu site	
	Azacitidine	MDS	China	2021	Co-developed formulation in China	
Lee's	Fondaparinux	Anti-thrombotic	China	2021		
Pharma	Travoprost & Bimatoprost	Glaucoma	China	2021	Co-development collaboration	
Nanjing King Friend	Regadenoson	Stress agent for heart scan	China	2020	Co-developed formulation in China	
US partner	Project A	Non-small cell lung cancer	US	2017	US NDA 505(b)(2) / The estimated launch year is subject to US FDA review	
US & China partners	Project B	Imaging agent	US	2021	ANDA with Paragraph IV filing / The estimated launch year is subject to litigation results	
Baxter	5 niche injectables	Anti-cancer & antinauseant	US/EU	2020& continuing thereafter	Baxter has the right to add up to 15 additional injectable products for collaboration	
Indian Int'l partner	Niche injectable	Anti-thrombotic	US/EU	2018	1st self-developed US ANDA launched. Executive right for marketing & sales	

Injectable Products Allied with Baxter

- ScinoPharm and Baxter Healthcare establish worldwide partnerships to co-develop and commercialize five niche generic injectable products at the initial stage
- ScinoPharm develops all APIs and injectable formulations. Baxter leads regulatory submissions in the US/EU and eventually market & sell the injectable products via its extensive presence in the hospital channel
- Both parties work on a cost-and-profit-sharing collaboration model
- Baxter has the right to add up to 15 additional injectable products for collaboration with ScinoPharm




Collaboration Framework

- Initial product portfolio including the generic injectables for breast cancer, lung cancer, multiple myeloma and antinauseant. Targeting US/EU markets first and expect to expand to other territories
- This exclusive partnership will utilize each other's strengths and expertise in order to achieve large scale of synergies in providing niche and affordable generic injectable products
- Commercial launch for the first 5 products upon FDA approval, with product launches beginning in 2020 and continuing thereafter
- Current branded sales of the initial five products included in this partnership total more than \$4 billion annually



Responsibilities by ScinoPharm and Baxter



Benefits of the Collaboration

- Aggressively expanding our "Double A" strategy for inhouse developed/produced APIs and formulations. Providing an outlet for our injectable plant capacity
- A win-win solution and collaboration. ScinoPharm provides comprehensive APIs and formulation portfolio, while Baxter operates strong injectable product marketing channels throughout the US and worldwide
- Accelerate the momentum of our downstream integration strategy by establishing alliance with an world-renowned partner



Maintain Market Share of Existing APIs 2016 Major Products account for 65% of total sales

ΑΡΙ	Indication	2016 MKT share*	# of US DMF/EDMF & other filings
Irinotecan HCI	Antineoplastic	42%	63
Paclitaxel	Antineoplastic	34%	57
Gemcitabine	Antineoplastic	24%	76
Exemestane	Antineoplastic	22%	44
Galantamine HBr	Antipsychotic	17%	38
Docetaxel Anhydrous	Antineoplastic	15%	69

*Source: IMS data from Newport



2017 Product Launch Plan

Туре	Product	Region	Indication	Brand Marketer	Regional Sales	WW Sales
Generic API	Desmopressin Acetate	USA	Polyuria	Ferring	US\$166M	US\$405M
Generic API	Tamsulosin HCl	USA	Benign Prostatic Hyperplasia (BPH)	Boehringer Ingelheim	US\$333M	US\$1706M
New Drug API	Oncology Product	US	Non-Small Cell Lung Cancer	N/A	N/A	N/A
New Drug API	Oral Product	USA EU	Antibiotics	N/A	N/A	N/A
Generic Drug	Oncology Injectable	US	Myeloid Leukemia	MDS	US\$183M	US\$278M




Source: IMS Data (2015Q3-2016Q2)

Pipeline Outlook

✓ 2 generic API launches
 ✓ 1st co-developed US ANDA launched

- ✓ 5-6 new launches
- ✓ 1 drug products launched in US
- ✓ Chinese (CFDA) inspection at Changshu site
- ✓ US FDA inspection at Injectable plant



34



Brand Quality with Asian Advantages www.scinopharm.com

